• argenx announces validation of European marketing authorization application for Efgartigimod in generalized myasthenia gravis

    Wednesday August 25th 2021

  • Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science

    Tuesday August 17th 2021

  • Precirix enters into alliance with 3P Biopharmaceuticals for the manufacturing of single domain antibodies

    Tuesday August 17th 2021

  • Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

    Wednesday July 28th 2021

  • Allegro inaugrates new lab at Bluechem

    Tuesday July 27th 2021

  • eTheRNA immunotherapies appoints Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc. located in the U.S.A

    Tuesday July 27th 2021

  • Biocair opens new office in South Africa, a clinical research hub

    Wednesday July 21st 2021

  • Bone Therapeutics provides update on the progress of clinical studies

    Monday July 19th 2021

  • Your news here?

  • Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands

    Thursday July 15th 2021

  • ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

    Thursday July 15th 2021

  • Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Thursday July 15th 2021


Strategic Partners